title: Disease Interception: Myths, Mountains, and Mole Hills.
abstract: Malignant diseases develop slowly over time and are often preceded by identifiable premalignancies. As malignancy progresses, so does genomic complexity and the ability of cancers to evade most therapeutic interventions. Accordingly, with some notable exceptions, a relatively low percentage of advanced cancers are effectively treated and even fewer are cured. Despite this appreciation, much less attention has been paid to intercepting the disease process compared with that of treating well-established and refractory disease. One frequently cited reason is that the pharmaceutical industry is not interested in these pursuits. In this commentary, we attempt to define the true hurdles, the degree of difficulty inherent in each, and some important approaches to be considered. Cancer Prev Res; 9(8); 635-7. ©2016 AACR.
authors.affiliation: Janssen Research and Development LLC., Raritan, New Jersey. whait@its.jnj.com.
authors.forename: William N
authors.initials: WN
authors.lastname: Hait
authors.affiliation: Janssen Research and Development LLC., Spring House, Pennsylvania.
authors.forename: Peter F
authors.initials: PF
authors.lastname: Lebowitz
mesh_terms: D015195:Drug Design; D004345:Drug Industry / Q000191:economics; D006801:Humans; D009369:Neoplasms / Q000517:prevention & control*; D000073296:Noncommunicable Diseases / Q000517:prevention & control; D011322:Primary Prevention / Q000191:economics / Q000639:trends